Anti-VEGF outperforms grid laser treatment for macular edema after BRVO
The prospective randomized trial included 36 patients with vision loss in one eye from macular edema attributed to BRVO. A study group comprising 15 patients was randomized to receive six monthly injections of 0.5 mg Lucentis (ranibizumab, Genentech) and monthly as-needed injections. A control group of 21 patients underwent sham injections for 1 year.
Grid laser treatment was performed at 13 weeks and 25 weeks in patients in both groups who met criteria for laser treatment.
Patients in the ranibizumab group gained a mean of 12.5 letters at 12 months, and those in the sham injection group lost a mean of 1.6 letters. The between-group difference was statistically significant (P = .032). Central foveal thickness decreased significantly more in the ranibizumab group than in the sham group (P = .025).
More patients in the sham group underwent grid laser treatment than those in the treatment group.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.